Detail akcie ADMA Biologics online

Business Summary: ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.
Financial Summary: BRIEF: For the six months ended 30 June 2017, ADMA Biologics Inc revenues increased 37% to $6M. Net loss increased 47% to $15.6M. Revenues reflect Plasma Collection Center segment increase of 25% to $5.4M. Higher net loss reflects Corporate segment loss increase from $3.8M to $8.9M, Plasma Collection Center segment loss increase of 29% to $1.1M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.93 to -$1.06.